RxDoctor Payments Data

Linda Callaghan, MD

Psychiatry · Washington, INNPI 1477768786

Payments from drug & device makers

$3,223in general payments, 2019–2025

Across 215 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$594
  • Vanda Pharmaceuticals Inc.$357
  • Alkermes, Inc.$311
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$280
  • Otsuka America Pharmaceutical, Inc.$279
  • Teva Pharmaceuticals USA, Inc.$264
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,16898%
  • Education$552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,223 in reported general payments places this provider in the 80th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$48,948
Medicare patients
98
Services billed
502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate72$131,390
VraylarCariprazine Hcl60$97,026
TrintellixVortioxetine Hydrobromide77$55,336
RexultiBrexpiprazole25$37,774
AuvelityDextromethorphan Hbr/Bupropion24$27,347
FetzimaLevomilnacipran Hcl40$20,183
BelsomraSuvorexant37$16,708
AzstarysSerdexmethylphen/Dexmethylphen21$9,048
QuviviqDaridorexant Hcl16$7,520
Divalproex Sodium56$7,222
VyvanseLisdexamfetamine Dimesylate14$5,540
Desvenlafaxine Succinate ErDesvenlafaxine Succinate25$5,319
Vilazodone Hcl46$4,923
Lisdexamfetamine Dimesylate15$3,963
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine147$3,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$280$131,39072 claims
AbbVieVraylar, Fetzima$594$117,209100 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$68$60,87791 claims
Otsuka America Pharmaceutical, Inc.Rexulti$279$37,77425 claims
Axsome Therapeutics, Inc.Auvelity$60$27,34724 claims
Corium, LLCAzstarys$113$9,04821 claims
Idorsia Pharmaceuticals US IncQuviviq$16$7,52016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 514 psychiatry providers in Indiana.

Other psychiatry in Washington

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →